Biogen Idec inc. (BIIB-NASDAQ) is trading up roughly 4% pre-market at $51.40, within striking distance of its $52.72 high over the last year on news of a share buyback plan. That is also the…
If you thought the day would never come that Dendreon (DNDN-NASDAQ) would see its volatility, its hyperactive volume, and its options premium compress to something back to almost normal, guess again: it came. The…
Stock Tickers: DNA, AMGN, NFLD, CELG, GILD, GENZ, ONXX, DNDN Jim Cramer has a video on TheStreet.com "Wall St. Confidential" showing how the biotech sector can be looked at with blow-ups. For every small…
Stock Tickers: AMGN, GILD, CELG, GENZ, MEDI, BIIB, AMLN, IMCL, DNDN, NFLD The short interest is on the rise overall, but the odd thing is that the short interest in biotech shares is really…
Northfield Laboratories Inc. (NFLD-NASDAQ) has probably just joined the ranks of the biotech zombies after the drop witnessed yesterday and today. The truth is that this may not be a true biotech because they…
Dendreon Corp. (DNDN-NASDAQ) was downgraded from an “Outperform” rating to a “Market Perform” rating. The brokerage sees uncertainties and risks going into an expected meeting FDA meeting over the recent “approvable and request for…
Cypress Biosciences (CYPB-NASDAQ) is literally a ‘double" in pre-market trading. Forest Labs (FRX-NYSE) and the company released top-line Phase III results that show statistically significant therapeutic effects of milnacipran as a treatment of fibromyalgia…
Northfield Labs (NFLD-NASDAQ) just faced what may the knockout blow for the company. The company has been working for years now on studies for PolyHeme, its blood substitution product. This product has been touted…
Some sectors showed mixed results in the short selling, but the Big Pharma and medical instruments and related companies saw an increased activity in short selling in May versus April. Below is the actual…
Medtronic (MDT-NYSE) posted quarterly results with revenues up 75 to $3.28 Billion, helped on currency by $71 million. Net earnings were 4812 million, or $0.70 EPS but $0.66 adjusting for charges and tax benefits. …
Since Dendreon (DNDN) has gotten a bit of life this week, there have been numerous inquiries as to "Where is this stock going?" from stock investors. There is obviously some hope by investors that…
Antigenics (AGEN-NASDAQ) saw its shares pop more than 20% as it released data in apress release regarding its Oncophage trials. The company’s follow-up ‘end of study’ data on Phase III therapeutic cancer cvaccines showed…
Dendreon (DNDN-NASDAQ) has an interesting twist this morning because of two issues. Yesterday it announced some new study data on PROVENGE at The American Urological Association on Sunday. The company’s board has also approved…
This morning there was a micro-cap biotech that focuses primarily on dermatological issues, made what could be an interesting acquisition for the treatment of Psoriasis. CollaGenex Pharmaceuticals, Inc. (CGPI-NASDAQ) and QuatRx Pharmaceuticals Company today…
At about 5:20 this morning after rolling the calendar a day over to see the notes, something stood out like a sore thumb: DENDREON DO OR DIE DATE! The truth is that the May…